Perspectives from Young South African and Zimbabwean Women on Attributes of Four (Placebo) Vaginal Microbicide Delivery Forms
- PMID: 31254190
- PMCID: PMC6988116
- DOI: 10.1007/s10461-019-02576-8
Perspectives from Young South African and Zimbabwean Women on Attributes of Four (Placebo) Vaginal Microbicide Delivery Forms
Abstract
Introduction: Incorporating end-user input into the design of new vaginal microbicides for women is key to optimizing their uptake, consistent use, and, ultimately, success in combatting the heterosexual HIV epidemic.
Methods: The Quatro Study assessed four placebo forms of vaginally inserted HIV-microbicides among young microbicide-naïve African women: on-demand film, insert and gel, and monthly ring. Participants randomly used each product for 1 month and provided product satisfaction ratings (1-5 scale), and opinions on product attributes and potential alternative designs. Qualitative data were collected through focus group discussions at study exit. Multivariable associations between attribute opinions and overall product rating were examined using Poisson regression models with robust standard errors to assess the attributes most influential to satisfaction.
Results: Overall opinions of products and their individual attributes were generally positive; all products were rated either 4 or a 5 by ≥ 50% of participants. Attributes related to ease of use and interference with normal activities were the most salient predictors of satisfaction. Preferences for duration of use tended toward relatively shorter use periods for the ring (i.e., 1-3 months vs. 12 months) and for coitally independent dosing for the on-demand products.
Conclusions: How well a product fit in with participants' lifestyles was important to their overall satisfaction. For on-demand products, greater flexibility around timing of use was desired, to avoid coital dependency of the dosing.
Keywords: Acceptability; Africa; African women; End-user research; HIV prevention; Microbicides; Product attributes.
Figures


Similar articles
-
The acceptability of an investigational vaginal microbicide, PRO 2000 Gel, among women in a phase I clinical trial.J Womens Health (Larchmt). 2003 Sep;12(7):655-66. doi: 10.1089/154099903322404302. J Womens Health (Larchmt). 2003. PMID: 14583106 Clinical Trial.
-
End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study.J Int AIDS Soc. 2019 May;22(5):e25283. doi: 10.1002/jia2.25283. J Int AIDS Soc. 2019. PMID: 31069957 Free PMC article. Clinical Trial.
-
Young Women's Ratings of Three Placebo Multipurpose Prevention Technologies for HIV and Pregnancy Prevention in a Randomized, Cross-Over Study in Kenya and South Africa.AIDS Behav. 2018 Aug;22(8):2662-2673. doi: 10.1007/s10461-018-2078-5. AIDS Behav. 2018. PMID: 29560570 Free PMC article. Clinical Trial.
-
Optimizing HIV prevention for women: a review of evidence from microbicide studies and considerations for gender-sensitive microbicide introduction.J Int AIDS Soc. 2015 Dec 21;18(1):20536. doi: 10.7448/IAS.18.1.20536. eCollection 2015. J Int AIDS Soc. 2015. PMID: 26700845 Free PMC article. Review.
-
On-demand microbicide products: design matters.Drug Deliv Transl Res. 2017 Dec;7(6):775-795. doi: 10.1007/s13346-017-0385-4. Drug Deliv Transl Res. 2017. PMID: 28589452 Free PMC article. Review.
Cited by
-
Strategic actions to advance multipurpose prevention technologies in low- and middle-income countries.Front Reprod Health. 2023 Jul 3;5:1150857. doi: 10.3389/frph.2023.1150857. eCollection 2023. Front Reprod Health. 2023. PMID: 37465533 Free PMC article. Review.
-
Acceptability and Preference for 3-Month Versus 1-Month Vaginal Rings for HIV-1 Risk Reduction Among Participants in a Phase 1 Trial.J Womens Health (Larchmt). 2022 Jul;31(7):1029-1039. doi: 10.1089/jwh.2021.0121. Epub 2021 Oct 19. J Womens Health (Larchmt). 2022. PMID: 34665672 Free PMC article. Clinical Trial.
-
Efficacy of silk fibroin biomaterial vehicle for in vivo mucosal delivery of Griffithsin and protection against HIV and SHIV infection ex vivo.J Int AIDS Soc. 2020 Oct;23(10):e25628. doi: 10.1002/jia2.25628. J Int AIDS Soc. 2020. PMID: 33073530 Free PMC article.
-
Users' Preferred Characteristics of Vaginal Rings for HIV Prevention: A Qualitative Analysis of Two Phase I Trials.AIDS Res Hum Retroviruses. 2022 Apr;38(4):313-326. doi: 10.1089/AID.2021.0077. Epub 2022 Feb 11. AIDS Res Hum Retroviruses. 2022. PMID: 34969254 Free PMC article. Clinical Trial.
-
HIV Prevention Product Acceptability and Preference Among Women in Sub-Saharan Africa to Inform Novel Biomedical Options in Development: A Systematic Review.AIDS Behav. 2025 Jan;29(1):257-293. doi: 10.1007/s10461-024-04529-2. Epub 2024 Oct 18. AIDS Behav. 2025. PMID: 39422786
References
-
- Rees H, Delany-Morelwe S, Lombard C, et al. FACTS 001 Phase III trial of pericoital tenofovir 1% gel for HIV prevention in women. In: Paper presented at: Conference on Retroviruses and Opportunistic Infections, Boston 2015.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical